5,750 Shares of Amgen Inc. $AMGN Bought by Greg Jennings LLC

Greg Jennings LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 5,750 shares of the medical research company’s stock, valued at approximately $2,424,000. Amgen makes up approximately 1.6% of Greg Jennings LLC’s portfolio, making the stock its 20th biggest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Wellington Altus USA Inc. increased its holdings in shares of Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 34 shares during the last quarter. Tower View Wealth Management LLC lifted its holdings in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares during the last quarter. Nvwm LLC lifted its holdings in Amgen by 412.5% in the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares during the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen during the second quarter worth approximately $36,000. Finally, Steph & Co. bought a new stake in Amgen during the third quarter worth approximately $42,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock traded down $7.55 during trading on Monday, hitting $424.94. 2,681,575 shares of the company’s stock traded hands, compared to its average volume of 2,758,142. The company has a market cap of $229.74 billion, a PE ratio of 26.41, a PEG ratio of 3.17 and a beta of 0.41. The firm’s fifty day moving average price is $415.54 and its 200 day moving average price is $374.94. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter last year, the company earned $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on AMGN shares. Morgan Stanley lowered their price target on Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 7th. Mizuho boosted their price objective on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. TD Cowen upped their price objective on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Piper Sandler upped their price objective on shares of Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Finally, Argus raised their target price on shares of Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $387.93.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last three months. 0.85% of the stock is owned by company insiders.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Australia’s Pharmaceutical Benefits Advisory Committee conditionally backed coverage for Imdelltra, Amgen’s treatment for small-cell lung cancer. A reimbursement decision could improve patient access and support future sales, although the conditional nature leaves implementation and approval details unresolved. PBAC conditionally backs Imdelltra
• Positive Sentiment: Exchange-traded funds reportedly purchased approximately $19.4 million of Amgen shares on October 15, indicating institutional demand and potentially providing technical support. Such flows are supportive but do not change the company’s underlying earnings outlook. ETFs Bought $19.4 Million of Amgen
• Neutral Sentiment: Several reports highlight Amgen’s broad portfolio, dividend, and potential growth from newer therapies. Zacks coverage mainly reflects increased investor attention rather than a new operational catalyst or change in estimates. Amgen: The Biotech Pioneer Preparing for Its Next Growth Wave
• Negative Sentiment: Analysts and market commentary emphasize that Amgen now needs stronger growth to justify its valuation. Mature products generate dependable cash flow and support the dividend, but investors are looking for faster expansion from newer drugs, making pipeline execution and commercial uptake key risks. Amgen Has the Drugs and the Dividend

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.